Moderna Inc. [NASDAQ: MRNA] disclosed that its COVID-19 vaccine has been granted the authorization by FDA to be stored at room temperature conditions once separated from the refrigerator for inoculation for 24 hours, an increase in intensity from the previous 12 hours. The authorization by FDA is based on the presented stability data by the firm.
Moreover, a pierced bottle is now can be used for up to 12 hours. It represents a rise from the earlier 6 hours. These new regulations are mirrored in a revised Emergency Use Authorization (EUA) label. The Moderna COVID-19 Vaccine is ready to use and does not need to be watered down.
Moderna disclosed that US FDA has also approved the incorporation of a new vial introduction with the highest possible of 15 doses of its COVID-19 vaccine. At the same time, the FDA also permitted the maximum limit of 11 doses of its COVID-19 vaccine in the existing system, from the earlier approved 10 doses per vial.
Furthermore, it has been revealed by the firm that its COVID-19 Vaccine now can be delivered in two vial introductions. One is a multiple-dose vial that contains the maximum limit of 11 doses or a multiple-dose vial containing the maximum limit of 15 doses. The firm anticipates that the shipping of the 15-dose vials will commence in the upcoming weeks.
Steps to Increase Vaccine Administration
Moderna Inc is continuously striving to jointly collaborate with its associates to speed up vaccine inoculation, tackle blockages, and speed up production. The firm has pinpointed the limitation in the production process. The limitation is the capacity of the fill-and-finish process.
Furthermore, MRNA has also pinpointed the option of adding additional doses to each vial of vaccine to tackle the blockages, speed up manufacturing capacity and decrease the need for replaceable materials that are in great demand. MRNA is also striving to collaborate with its partners and the US government to speed up its production capacity.